Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Jumping Today

By Keith Speights – Sep 9, 2020 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two developments could improve the biotech's prospects of receiving federal funding for its coronavirus vaccine program.

What happened

Shares of Inovio Pharmaceuticals (INO 3.12%) were jumping 8.9% as of 11:09 a.m. EDT on Wednesday after rising as much as 23.6% earlier in the day. Investors appear to be more confident about Inovio's potential to receive federal funding for its COVID-19 vaccine candidate INO-4800 after two developments on Tuesday.

First, Inovio announced that it had signed a letter of intent with Thermo Fisher Scientific (TMO -0.28%) to manufacture 100 million doses of INO-4800 in 2021. Second, AstraZeneca (AZN 0.19%) revealed that it has temporarily paused a late-stage clinical study of its coronavirus vaccine candidate AZD1222 after a participant experienced a severe adverse reaction.

Bottles labeled "COVID-19 vaccine" and syringe on top of $100 bills

Image source: Getty Images.

So what

Inovio hasn't received a large funding commitment from the U.S. government's Operation Warp Speed (OWS) program so far. However, the company is farther along in clinical testing with INO-4800 than some other drugmakers that have received significant funding from OWS. One potential reason why that's the case is that in the past Inovio's capacity for manufacturing INO-4800 was only a fraction of the capacity of others in the race to develop coronavirus vaccines.

Now, though, Inovio's deal with Thermo Fisher Scientific could change the dynamics. The capability to produce 100 million doses of INO-4800 just might catch the attention of OWS or the governments of other countries hoping to secure COVID-19 vaccines.

At the same time, the potential safety issue with AstraZeneca's COVID-19 vaccine candidate could spur OWS to consider adding another investigational vaccine to its roster of funded programs. The U.S. committed $1.2 billion in funding to the big drugmaker in May to secure 300 million doses of AZD1222. 

Now what

There's no guarantee that Inovio will receive significant funding for INO-4800. But it's certainly a possibility. The most important thing for the biotech stock right now isn't funding, though; it's the initiation of a phase 2/3 study for the investigational COVID-19 vaccine. Inovio hopes to receive a green light from the FDA to begin this study this month. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$1.98 (3.12%) $0.06
AstraZeneca Plc Stock Quote
AstraZeneca Plc
$68.47 (0.19%) $0.13
Thermo Fisher Scientific Stock Quote
Thermo Fisher Scientific
$563.00 (-0.28%) $-1.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.